| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Departments of Nuclear Medicine and Breast and Gynecologic Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas
Correspondence: For correspondence or reprints contact: E. Edmund Kim, MD, Department of Nuclear Medicine, Box 59, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030.
ABSTRACT
We retrospectively investigated the value of PET with fluorine-18-fluorodeoxyglucose (FDG) for preoperative chemotherapy response in patients with locally advanced breast cancer. Methods: FDG-PET studies were performed on 16 consecutive patients. All patients had PET studies before chemotherapy, 13 patients between the end of the first cycle and at the midpoint of chemotherapy, and 14 patients before surgery. Visual diagnoses and the standardized uptake values (SUV) of PET scans were compared with pathology findings at surgery and with the results of mammography, ultrasonography (US) or both, which were performed before chemotherapy and before local surgery for residual disease. Each patient's clinical course was monitored for up to 3 yr. Results: Sensitivity for detection of pathologically proven primary lesions was 100%, 62.5% and 87.5% with FDG-PET, mammography and US, respectively; and sensitivity for detection of initial nodal involvement was 77%, 70% and 87.5%, respectively. Sensitivity for detection of residual primary tumor was 75%, 71.4% and 87.5%, respectively; and sensitivity for detection of residual nodal involvement was 41.6%, 71.4% and 66.6%, respectively. The mean SUV value of primary lesions was 9.4 (range 2.0–20.7, n = 16), with only two lesions showing an SUV below 3. Clinical improvement of primary lesions was seen in all patients; improvement with smaller size and less FDG uptake was visible as early as the second study in 11 patients (69%). Mean SUV values obtained at the second and third studies decreased significantly from those obtained in the first study. In four patients, the disease recurred after breast surgery with high SUV values. The mammograms and sonograms obtained before surgery showed a decrease in the diameter of 6 and 12 primary lesions of the 13 and 14 patients examined, respectively. Conclusion: FDG-PET is valuable for monitoring the effects of preoperative chemotherapy in patients with locally advanced breast cancer with better sensitivity for primary tumor and better specificity for nodal metastasis in comparison with ultrasonography.
Key Words: PET • fluorine-18-fluorodeoxyglucose • breast cancer • preoperative chemotherapy
This article has been cited by other articles:
|
|
 |
|
  J. Emmering, N. C. Krak, J. J. M. Van der Hoeven, M. D. Spreeuwenberg, J. W. R. Twisk, S. Meijer, H. M. Pinedo, and O. S. Hoekstra Preoperative [18F] FDG-PET after chemotherapy in locally advanced breast cancer: prognostic value as compared with histopathology Ann. Onc., September 1, 2008; 19(9): 1573 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Lim, W. Yoon, T. W. Chung, J. K. Kim, J. G. Park, H. K. Kang, H. S. Bom, and J. H. Yoon FDG PET/CT for the Detection and Evaluation of Breast Diseases: Usefulness and Limitations RadioGraphics, October 1, 2007; 27(suppl_1): S197 - S213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. L. Rosen, W. B. Eubank, and D. A. Mankoff FDG PET, PET/CT, and Breast Cancer Imaging RadioGraphics, October 1, 2007; 27(suppl_1): S215 - S229. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. K. Kuhl Current Status of Breast MR Imaging * Part 2. Clinical Applications Radiology, September 1, 2007; 244(3): 672 - 691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend PET/CT: Form and Function Radiology, February 1, 2007; 242(2): 360 - 385. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Rousseau, A. Devillers, C. Sagan, L. Ferrer, B. Bridji, L. Campion, M. Ricaud, E. Bourbouloux, I. Doutriaux, M. Clouet, et al. Monitoring of Early Response to Neoadjuvant Chemotherapy in Stage II and III Breast Cancer by [18F]Fluorodeoxyglucose Positron Emission Tomography J. Clin. Oncol., December 1, 2006; 24(34): 5366 - 5372. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Couturier, G. Jerusalem, J.-M. N'Guyen, and R. Hustinx Sequential Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Response to Chemotherapy in Metastatic Breast Cancer. Clin. Cancer Res., November 1, 2006; 12(21): 6437 - 6443. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Semple, R. Staff, S. Heys, T. Redpath, A. Welch, T. Ahearn, A. Hutcheon, and F. Gilbert Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration Ann. Onc., September 1, 2006; 17(9): 1393 - 1398. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cachin, H. M. Prince, A. Hogg, R. E. Ware, and R. J. Hicks Powerful Prognostic Stratification By [18F]Fluorodeoxyglucose Positron Emission Tomography in Patients With Metastatic Breast Cancer Treated With High-Dose Chemotherapy J. Clin. Oncol., July 1, 2006; 24(19): 3026 - 3031. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Sachelarie, M. L. Grossbard, M. Chadha, S. Feldman, M. Ghesani, and R. H. Blum Primary Systemic Therapy of Breast Cancer Oncologist, June 1, 2006; 11(6): 574 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Quon and S. S. Gambhir FDG-PET and Beyond: Molecular Breast Cancer Imaging J. Clin. Oncol., March 10, 2005; 23(8): 1664 - 1673. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Tseng, L. K. Dunnwald, E. K. Schubert, J. M. Link, S. Minoshima, M. Muzi, and D. A. Mankoff 18F-FDG Kinetics in Locally Advanced Breast Cancer: Correlation with Tumor Blood Flow and Changes in Response to Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2004; 45(11): 1829 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hamaoka, J. E. Madewell, D. A. Podoloff, G. N. Hortobagyi, and N. T. Ueno Bone Imaging in Metastatic Breast Cancer J. Clin. Oncol., July 15, 2004; 22(14): 2942 - 2953. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, E. K. Schubert, J. Tseng, T. J. Lawton, H. M. Linden, and R. B. Livingston Changes in Blood Flow and Metabolism in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy J. Nucl. Med., November 1, 2003; 44(11): 1806 - 1814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Weber, V. Petersen, B. Schmidt, L. Tyndale-Hines, T. Link, C. Peschel, and M. Schwaiger Positron Emission Tomography in Non-Small-Cell Lung Cancer: Prediction of Response to Chemotherapy by Quantitative Assessment of Glucose Use J. Clin. Oncol., July 15, 2003; 21(14): 2651 - 2657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kostakoglu and S. J. Goldsmith 18F-FDG PET Evaluation of the Response to Therapy for Lymphoma and for Breast, Lung, and Colorectal Carcinoma J. Nucl. Med., February 1, 2003; 44(2): 224 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. A. Mankoff, L. K. Dunnwald, J. R. Gralow, G. K. Ellis, A. Charlop, T. J. Lawton, E. K. Schubert, J. Tseng, and R. B. Livingston Blood Flow and Metabolism in Locally Advanced Breast Cancer: Relationship to Response to Therapy J. Nucl. Med., April 1, 2002; 43(4): 500 - 509. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vranjesevic, J. E. Filmont, J. Meta, D. H. Silverman, M. E. Phelps, J. Rao, P. E. Valk, and J. Czernin Whole-Body 18F-FDG PET and Conventional Imaging for Predicting Outcome in Previously Treated Breast Cancer Patients J. Nucl. Med., March 1, 2002; 43(3): 325 - 329. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Yap, M. A. Seltzer, C. Schiepers, S. S. Gambhir, J. Rao, M. E. Phelps, P. E. Valk, and J. Czernin Impact of Whole-Body 18F-FDG PET on Staging and Managing Patients with Breast Cancer: The Referring Physician's Perspective J. Nucl. Med., September 1, 2001; 42(9): 1334 - 1337. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. B. Eubank, D. A. Mankoff, J. Takasugi, H. Vesselle, J. F. Eary, T. J. Shanley, J. R. Gralow, A. Charlop, G. K. Ellis, K. L. Lindsley, et al. 18Fluorodeoxyglucose Positron Emission Tomography to Detect Mediastinal or Internal Mammary Metastases in Breast Cancer J. Clin. Oncol., August 1, 2001; 19(15): 3516 - 3523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Gambhir, J. Czernin, J. Schwimmer, D. H. S. Silverman, R. E. Coleman, and M. E. Phelps A Tabulated Summary of the FDG PET Literature J. Nucl. Med., May 1, 2001; 42(90050): 1S - 93. [Full Text] [PDF]
|
|
|
|
|
|
N. Avril, C. A. Rose, M. Schelling, J. Dose, W. Kuhn, S. Bense, W. Weber, S. Ziegler, H. Graeff, and M. Schwaiger Breast Imaging With Positron Emission Tomography and Fluorine-18 Fluorodeoxyglucose: Use and Limitations J. Clin. Oncol., October 20, 2000; 18(20): 3495 - 3502. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Smith, A. E. Welch, A. W. Hutcheon, I. D. Miller, S. Payne, F. Chilcott, S. Waikar, T. Whitaker, A. K. Ah-See, O. Eremin, et al. Positron Emission Tomography Using [18F]-Fluorodeoxy-D-Glucose to Predict the Pathologic Response of Breast Cancer to Primary Chemotherapy J. Clin. Oncol., April 1, 2000; 18(8): 1676 - 1688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Schelling, N. Avril, J. Nahrig, W. Kuhn, W. Romer, D. Sattler, M. Werner, J. Dose, F. Janicke, H. Graeff, et al. Positron Emission Tomography Using [18F]Fluorodeoxyglucose for Monitoring Primary Chemotherapy in Breast Cancer J. Clin. Oncol., April 1, 2000; 18(8): 1689 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Romer, A.-R. Hanauske, S. Ziegler, R. Thodtmann, W. Weber, C. Fuchs, W. Enne, M. Herz, C. Nerl, M. Garbrecht, et al. Positron Emission Tomography in Non-Hodgkin's Lymphoma: Assessment of Chemotherapy With Fluorodeoxyglucose Blood, June 15, 1998; 91(12): 4464 - 4471. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |
